Cognitive dysfunction is a major comorbidity of the epilepsies; however, treatments targeting seizure-associated cognitive dysfunction, particularly deficits in learning and memory are not available. Isoketals and neuroketals, collectively known as gamma-ketoaldehydes are formed via the non-enzymatic, free radical catalyzed oxidation of arachidonic acid and docosahexaenoic acid, respectively. They are attractive candidates for oxidative protein damage and resultant cognitive dysfunction due to their formation within the plasma membrane and their high proclivity to form cytotoxic adducts on protein lysine residues. We tested the hypothesis that gammaketoaldehydes mechanistically contribute to seizure-associated memory impairment using a specific gammaketoaldehyde scavenger, salicylamine in the kainic acid and pilocarpine rat models of temporal lobe epilepsy. We show that gamma-ketoaldehydes are increased following epileptogenic injury in hippocampus and perirhinal cortex, two brain regions imperative for learning and memory. Treatment with an orally bioavailable, brain permeable scavenger, salicylamine attenuated 1) spatial memory deficits 2) reference memory deficits and 3) neuronal loss and astrogliosis in two mechanistically distinct models of epilepsy without affecting the epileptogenic injury or the development of chronic epilepsy. We have previously demonstrated that reactive oxygen species and the lipid peroxidation biomarkers, F 2 -isoprostanes are produced following status epilepticus. However, which reactive species specifically mediate oxidative damage to cellular macromolecules remains at large. We provide novel data suggesting that memory impairment occurs via gamma-ketoaldehyde production in two models of epilepsy and that treatment with a gamma-ketoaldehyde scavenger can protect vulnerable neurons. This work suggests a novel target and therapy to treat seizure-induced memory deficits in epilepsy.
Introduction
Up to half of people with temporal lobe epilepsy (TLE) report experiencing one or more cognitive deficits (Gilliam et al., 2003) . Quality of life correlates with the comorbid cognitive conditions rather than the seizures themselves, indicating that memory impairment represents a larger burden to patients than experiencing unpredictable seizures (Gilliam et al., 2003) . Cognitive comorbidities of epilepsy, particularly memory impairment, are widely recognized for their frequent and debilitating nature, however there are currently no therapies to treat them and the mechanism(s) by which cognitive dysfunction arises during epilepsy are unknown.
A growing body of research has implicated oxidative stress as a contributing factor to cognitive impairment in disorders including Alzheimer's disease (AD) and recently TLE (Berr et al., 2000; Pearson et al., 2015; Praticò et al., 2002) . However, the precise mechanism(s) and species mediating oxidative damage remains unknown. Identification of specific species mediating damage is imperative as some reactive oxygen species (ROS) have recently been recognized for their signaling roles (Rhee, 2006; Thiels et al., 2000) . The brain is uniquely susceptible to oxidative damage, specifically lipid peroxidation, due to its high oxygen demand and polyunsaturated fatty acid (PUFA) composition. Arachidonic acid is one such PUFA that is highly enriched in the brain and together with docosahexaenoic acid accounts for a large portion of the brain's fatty acid content. Under conditions of oxidative stress, tissue esterified arachidonic acid and docosahexaenoic acid are susceptible to free radical-induced peroxidation forming F 2 -Isoprostanes (F 2 -IsoPs) and F 4 -Neuroprostanes, respectively (Milne et al., 2011 
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